1. HBW Insight
  2. >>Supply Chain

Nestlé Hit By US Supply Chain Issue Expected To Impact VMS Sales Into 2024

 
• By Tom Gallen

Nestlé insists it is “on top of” an unexpected supply chain problem which emerged in the US in August and has since hit sales of its dietary supplements in North America. The company revealed the issue as it reported flat sales at its Health Science business for the opening nine months of 2023.

Supply Chain Issues Text With Chain Image
• Source: Shutterstock

Nestlé Health Science has been blindsided by a supply chain problem impacting vitamin, mineral and supplement sales in North America.

An IT integration issue which surfaced in August during work to consolidate its US VMS packaging sites led to supply...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

Wellness Firms Targeting GLP-1 Patients’ Dietary Needs Keep Option To Provide Access To Oral Rx

Health and wellness brands and retail chains providing access to prescriptions for compounded GLP-1 drugs, most also offering supplements curated to help meet dietary needs of GLP-1 patients, are offering formulations in oral form as well as injection.

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By David Ridley

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 
• By Malcolm Spicer

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 
• By Malcolm Spicer

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

More from HBW Insight

MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders – Attorney

 
• By Eileen Francis

The delay in implementation of MoCRA is seen by many companies as a temporary reprieve, but it does create more legal uncertainty, says attorney Marissa Alkhazov of law firm Buchalter.

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.